Locally Advanced Laryngeal Cancer: Cisplatin Dosing Against Renal and Hearing Risk
Curative-intent chemoradiation needs a platinum agent that is, in this particular patient, dangerous to both organs it's known to damage — and the alternative that spares both carries a real efficacy cost the team can't pretend away.
Walter B. has supervised construction crews for close to forty years, work that put him on job sites next to jackhammers and pile drivers for decades before hearing protection was standard practice, and left him with bilateral high-frequency hearing loss he's worn hearing aids for since his mid-fifties. He came in for a persistent hoarseness he'd attributed to "talking over machinery my whole life," and laryngoscopy instead found a T3N2 squamous cell carcinoma of the larynx, HPV-negative on testing, staged as locally advanced but still within a curative-intent window with concurrent chemoradiation. He has longstanding hypertension and, on today's labs, a creatinine of 1.6 with an estimated glomerular filtration rate near 42 — chronic kidney disease his primary care physician has attributed to years of over-the-counter anti-inflammatory use layered on the hypertension itself, tracked but not previously treated with anything beyond dietary counseling.
The regimen question the team is actually arguing isn't whether he needs concurrent chemoradiation — the tumor stage settles that — it's which drug, because the two organ systems cisplatin is best known for damaging are both already compromised in him, in opposite directions that no single dose adjustment cleanly protects. The MACH-NC meta-analysis is what makes cisplatin the actual standard here, showing a real survival advantage for concurrent platinum chemoradiation over radiation alone; RTOG 0522, by contrast, found no benefit from adding cetuximab to cisplatin-radiation — evidence that cuts against cetuximab as an add-on but says nothing about cetuximab used as a substitute, which is the question his kidneys and ears actually pose. The trial that did test substitution outside the HPV-positive setting, ARTSCAN III, closed early with locoregional failure at three years running more than double in the cetuximab arm, without a measured difference in overall survival — so substituting is not a free trade, and the size of what is being traded away is known rather than hypothetical. Reduced-dose weekly cisplatin schedules exist specifically to lower cumulative exposure, though the literature comparing weekly to the standard high-dose regimen remains genuinely mixed on whether the two are equivalent rather than merely similar — a real uncertainty the team has to weigh rather than resolve by citation alone.
Tumor board, chemoradiation planning
Cisplatin is the standard for a reason — MACH-NC's survival advantage for concurrent platinum chemoradiation over radiation alone is the actual evidentiary floor here, and the trial that actually tested substitution in an HPV-unselected locally advanced population — ARTSCAN III — was stopped early because locoregional failure at three years ran more than twice as high in the cetuximab arm as in the cisplatin arm. That is the number I'd want on the table before anyone treats cetuximab as a lateral move rather than a downgrade. I'd use weekly low-dose cisplatin at 40 milligrams per square meter rather than the standard high-dose every-three-week schedule — a real, if more heterogeneous, evidence base for reducing cumulative exposure while keeping him on a platinum backbone.
I'd weigh the renal side more heavily than a dose reduction addresses. An eGFR near 40 means he's already meaningfully impaired, and even reduced cumulative cisplatin exposure carries real risk of a further step down — one that, in chronic kidney disease, doesn't reliably recover the way an acute injury might. If he loses another 30 percent of function during treatment, he's genuinely closer to needing renal replacement therapy than anyone at this table wants to be responsible for.
The weekly schedule reduces exposure, I agree — but reduces isn't the same as removes, and for a patient already this close to a functional floor, I'd rather avoid the drug's known mechanism of injury entirely than accept a smaller version of the same risk.
I want to bring the hearing side back into this explicitly, because it's been treated as secondary and I don't think it should be. He depends on hearing aids for his livelihood and daily function already — any cumulative cisplatin exposure, even a reduced dose, carries real ototoxic risk that could push him toward disabling deafness on top of the kidney concern.
And I'm not going to wave away the ARTSCAN III number — a doubled locoregional failure rate is exactly the cost I'm proposing he accept, and I'd rather name it than let it sit unstated. What I'd say against it is that ARTSCAN III enrolled patients fit for cisplatin, which he is not; the comparison it makes is between two options he does not both have. RTOG 0522's negative result is a different question again — adding cetuximab, not substituting it — and shouldn't be read as settling this either.
I take the renal argument seriously, and between the two of you I think it's the stronger one — an irreversible step toward dialysis is a graver outcome than accepting cetuximab's real but smaller efficacy trade-off. I'd move to cetuximab-radiation and protect both organ systems definitively rather than gamble either one on a reduced but nonzero cisplatin exposure.
Agreed: cetuximab with concurrent radiation, with baseline and on-treatment renal function and audiometry both tracked explicitly so the team has real data, not just intent, showing both organ systems held stable through treatment.
Not agreed: whether a reduced-dose platinum schedule would have been the better trade. The radiation oncologist's own preference, weekly low-dose cisplatin, was not adopted, but was not treated as wrong either — recorded as the position that would have been chosen if either organ risk alone, without the other, had been the sole constraint. With both present together, the team's judgment favored the option immune to both, even at a real efficacy cost none of them minimized.